01513 PE Ratio & Valuation, Is 01513 Overvalued

Historical Valuation

LIVZON PHARMA (01513) is now in the Fair zone, suggesting that its current forward PE ratio of 10.38 is considered Fairly compared with the five-year average of 10.69. The fair price of LIVZON PHARMA (01513) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：29.20

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is LIVZON PHARMA (01513) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

LIVZON PHARMA (01513) has a current Price-to-Book (P/B) ratio of 1.67. Compared to its 3-year average P/B ratio of 1.66, the current P/B ratio is approximately 1.01% higher. Relative to its 5-year average P/B ratio of 1.67, the current P/B ratio is about -0.19% higher. LIVZON PHARMA (01513) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 7.96%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.17%, the current FCF yield is about -100.00% lower.

Performance Decomposition

AI Analysis

Market capitalization of 01513 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 01513 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 01513 currently overvalued or undervalued?

What is LIVZON PHARMA (01513) fair value?

01513's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of LIVZON PHARMA (01513) is between to according to relative valuation method.

How does 01513's valuation metrics compare to the industry average?

The average P/S ratio for 01513's competitors is 0.00, providing a benchmark for relative valuation. LIVZON PHARMA Corp (01513) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for LIVZON PHARMA (01513) as of Apr 04 2026?

As of Apr 04 2026, LIVZON PHARMA (01513) has a P/B ratio of 1.67. This indicates that the market values 01513 at 1.67 times its book value.

What is the current FCF Yield for LIVZON PHARMA (01513) as of Apr 04 2026?

As of Apr 04 2026, LIVZON PHARMA (01513) has a FCF Yield of 0.00%. This means that for every dollar of LIVZON PHARMA's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for LIVZON PHARMA (01513) as of Apr 04 2026?

As of Apr 04 2026, LIVZON PHARMA (01513) has a Forward P/E ratio of 10.38. This means the market is willing to pay $10.38 for every dollar of LIVZON PHARMA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for LIVZON PHARMA (01513) as of Apr 04 2026?

As of Apr 04 2026, LIVZON PHARMA (01513) has a Forward P/S ratio of 0.00. This means the market is valuing 01513 at $0.00 for every dollar of expected revenue over the next 12 months.

01513 Valuation